NCT05462717 2026-04-08Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid TumorsRevolution Medicines, Inc.Phase 1 Active not recruiting222 enrolled
NCT07038369 2026-03-17A Phase 1 Study of ATV-1601 in Patients With Advanced Cancer That Have AKT1 E17K MutationsAtavistik Bio, IncPhase 1 Active not recruiting134 enrolled